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ABSTRACT
Background. Adipose tissue contributes to the inflammatory response through
production of cytokines, recruitment of macrophages and modulation of the
adiponectin system. Previous studies have identified a down-regulation of
adiponectin in pathologies characterised by acute (sepsis and endotoxaemia) and
chronic inflammation (obesity and type-II diabetes mellitus). In this study, we inves-
tigated the hypothesis that LPS would reduce adiponectin receptor expression in a
murine model of endotoxaemia and in adipoocyte and myocyte cell cultures.
Methods. 25 mg/kg LPS was injected intra-peritoneally into C57BL/6J mice,
equivalent volumes of normal saline were used in control animals. Mice were
killed at 4 or 24 h post injection and tissues harvested. Murine adipocytes
(3T3-L1) and myocytes (C2C12) were grown in standard culture, treated with LPS
(0.1 µg/ml–10 µg/ml) and harvested at 4 and 24 h. RNA was extracted and qPCR was
conducted according to standard protocols and relative expression was calculated.
Results. After LPS treatment there was a significant reduction after 4 h in gene
expression of adipo R1 in muscle and peri-renal fat and of adipo R2 in liver,
peri-renal fat and abdominal wall subcutaneous fat. After 24 h, significant reductions
were limited to muscle. Cell culture extracts showed varied changes with reduction in
adiponectin and adipo R2 gene expression only in adipocytes.
Conclusions. LPS reduced adiponectin receptor gene expression in several tissues
including adipocytes. This reflects a down-regulation of this anti-inflammatory and
insulin-sensitising pathway in response to LPS. The trend towards base line after 24 h
in tissue depots may reflect counter-regulatory mechanisms. Adiponectin receptor
regulation differs in the tissues investigated.
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INTRODUCTION
White Adipose Tissue (WAT) is now known to be a dynamic secretory organ in its own
right, secreting a number of compounds called adipokines (Robinson, Prins & Venkatesh,
2011). These biologically active proteins act as inflammatory mediators and play a major
role in metabolic derangements in chronic inflammatory disorders such as type 2 Diabetes
mellitus (DM) and the metabolic syndrome (Kadowaki et al., 2006; Kern et al., 2003).
Newer research has demonstrated inhibition of anti-inflammatory adipokines in acute
inflammatory processes such as severe sepsis (Welters et al., 2014). Similar responses are
also observed after lipopolysaccharide (LPS) challenge, which therefore provides a useful
model for the study of altered metabolism in inflammation (Agwunobi et al., 2000).
First described in the early 2000s, Adiponectin is a 30 kDa, 244-amino acid polypeptide,
which is mainly expressed in adipose tissue and has anti-inflammatory, anti-diabetic and
anti-atherogenic effects. It has a similar structure to complement factor C1q and accounts
for 0.01% of total plasma protein (Whitehead et al., 2006). Adiponectin increases glucose
utilisation and reduces insulin resistance by stimulating fatty acid oxidation which in turn
leads to reduced triglyceride concentration in skeletal muscle and liver (Fruebis et al., 2001;
Yamauchi et al., 2002). The anti-inflammatory effects of adiponectin include suppressed
proliferation of myeloid cell lines, reduction of the phagocytic ability of macrophages
and down-regulation of macrophage recruitment to sites of inflammation (Tsuchihashi et
al., 2006; Yokota et al., 2000). Adiponectin also reduces the production of inflammatory
cytokines from macrophages and adipose tissue (Park et al., 2008; Tsuchihashi et al.,
2006; Yokota et al., 2000). Observations of adiponectin in chronic disease such as type II
DM, obesity and cardiovascular disease identify consistent down-regulation of gene and
protein expression (Hu, Liang & Spiegelman, 1996; Maeda et al., 2002; Robinson, Prins &
Venkatesh, 2011). In acute inflammation, preliminary human studies have confirmed a
similar down-regulation of adiponectin (Welters et al., 2014) and small animal studies have
demonstrated a negative correlation with pro-inflammatory cytokine concentrations such
as Tumour Necrosis Factor-α (Bruun et al., 2003).
Two adiponectin receptors have been identified, adipoR1 and R2 (Yamauchi et al., 2003).
Both are expressed in numerous tissues including skeletal muscle, liver, adipose tissue and
pancreatic islet and acinar cells (Civitarese et al., 2004; Kharroubi et al., 2003; Tsuchida et al.,
2004). Previous studies have identified a down-regulation of adiponectin and its receptors
in pathologies characterised by chronic inflammation such as obesity and type-II DM
(Kadowaki & Yamauchi, 2005; Tsuchida et al., 2004). In a previous study, we demonstrated
the down-regulation of adiponectin gene and protein expression within different fat depots
24 h following LPS administration in mice (Leuwer et al., 2009). These results are in line
with reports on decreased circulating adiponectin levels in the plasma of septic patients
(Hillenbrand et al., 2010; Uji et al., 2009). However, to date, little is known about the
modulation of the adiponectin system in peripheral organs involved in glucose and lipid
metabolism, such as liver and skeletal muscle. It is tempting to speculate that global acute
inflammation elicits similar changes to the adiponectin system not only within the adipose
tissue itself, but also in peripheral tissues involved in lipid and glucose metabolism.
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In this study, we investigated the hypothesis that LPS reduces adiponectin receptor
expression in a murine model of endotoxaemia and also in mouse fat and muscle isolated
cell lines.
MATERIALS AND METHODS
Animal experiments
All experiments were carried out on 8 to 10-week-old male C57BL/6J mice (Charles
River, Oxford, UK). All experimental procedures were approved by the UK Home
Office and were conducted in accordance with the appropriate Project License (PPL
40/2692). Mice were housed in separate cages post procedures and maintained in the
same temperature-controlled conditions (22± 2 ◦C, 12 h light/12 h dark cycle) with free
access to a standard laboratory rodent diet and water. LPS (25 mg/kg, Escherichia coli
O 111:B4, Sigma-Aldrich) was injected intra-peritoneally (ip) under general anaesthesia
(2% isoflurane in N2O/O2). All animals received 1 ml of normal saline subcutaneously
(SC) at time of LPS injection to compensate for fluid losses. Control animals received an
equivalent volume of normal saline i.p. Both control and LPS treated mice were killed at
4 (n = 6) and 24 h (n = 9), respectively, after injection by cervical dislocation. Based on
recommendations by the UK Home Office, sample sizes were reduced to the minimum
number expected to yield significant results. Similar studies required <10 animals per
group to demonstrate significant changes (Leuwer et al., 2009). Peri-renal fat (PRF),
epididymal fat (EF), abdominal wall subcutaneous fat (SCF), skeletal muscle (soleus
muscle) and liver were removed and immediately frozen in liquid nitrogen until analysis.
Cell culture
Isolated cell lines were used to investigate LPS effects on fat and muscle cells (3T3-L1
murine adipocytes and C2C12 murine myocytes). Cells were initiated in culture media
(Dulbecco’s modified Eagle medium (DMEM) (Sigma-Aldrich, Gillingham, Dorset, UK)
with 10% foetal calf serum (FCS) (3T3-L1 murine adipocytes) and 10% FCS with 1%
penicillin/streptomycin and L-glutamine (C2C12 murine myocytes). Cells were incubated
at 37 ◦C, in a humidified atmosphere of 95% air and 5% CO2 until confluence was
reached. 3T3-L1 adipocytes were differentiated by the addition of 10 mg/ml insulin, 1 mM
dexamethasone, and 100 mM IBMX in DMEM. C2C12 myocytes were differentiated with
2% horse serum. Cells were treated with different concentrations (0.1, 1, 5, 10 µg/ml) of
LPS (Escherichia coli O 111:B4, Sigma-Aldrich, Gillingham, Dorset, UK) and harvested at
4 and 24 h. Control experiments were performed using equivalent volumes of normal
saline. Each experiment was repeated at least six times. Untreated control cells were
harvested at the same time points.
RNA extraction and real time PCR
RNA extraction and reverse transcription were performed as previously described (Leuwer
et al., 2009). Briefly, total RNA was extracted from adipose tissues with Trizol reagent
(Invitrogen, UK), and 1 µg of DNase I-treated RNA was reverse transcribed using a
Reverse-iTTM 1ST Strand Synthesis Kit (Abgene, Epsom, UK) in the presence of anchored
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oligo dT in a total volume of 20 µl. Real-time PCR was conducted using TAQ Man (12.5 µl
reaction volume with 12.5 ng of cDNA with optimal concentrations of primers and probes
and qPCRTM Core kit (Eurogentec, UK) (Beta actin: Forward: ACGGCCAGGTCAT-
CACTATTG, Reverse: CAAGAAGGAAGGCTGGAAAAG, Adiponectin R1: Forward:
AGATGGAGGAGTTCGTGTA TAAGG, Reverse: GGCCATGTAGCAGGTAGTCG,
Adiponectin R2: Forward: CTTTCGGGCCTGTTTTAAGAGC, Reverse: ATATTTGGGC-
GAAACATATAAAAGATCC, Adiponectin: Forward: GGCTCTGTGCTCCTCCATCT,
Reverse: AGAGTCGTTGACGTTATCTGCATAG). All qPCR reactions were analysed with
the housekeeping gene β-actin.
Statistical analysis
Relative gene expression levels were determined using the 2-ddCt method (Livak &
Schmittgen, 2001). Data are presented as mean values ± Standard Error of Mean.
Differences between groups were analyzed by Student’s unpaired t-test or non-parametric
tests when data was non-normally distributed. In the animal model, treatment 4 h and 24 h
after LPS injection was compared with a respective control group. Results were considered
to be statistically significant when p < 0.05. Where multiple comparisons were performed
in the in vitro study, statistical significance was corrected using Bonferroni’s method for
each time point. Fold change was calculated as 1/2-ddCt.
RESULTS
Adiponectin receptors are down-regulated in murine
endotoxaemia
Expression of adiponectin receptors was detected in all murine tissues examined. 4 h
after treatment with LPS, there were significant reductions in adipoR1 gene expression in
skeletal muscle (9.8 fold reduction, p= 0.017) and peri-renal fat (PRF) (1.6 fold reduction,
p = 0.008) (Table 1A and Data S2). AdipoR2 gene expression decreased in liver (2.7 fold
reduction, p = 0.008), PRF (4.3 fold reduction, p = 0.004) and sub-cutaneous fat (SCF)
(2.9 fold reduction, p = 0.04). This represents a rapid response to treatment with LPS. In
mice treated with LPS for 24 h, there were significant reductions in the expression of both
receptors in skeletal muscle (adipoR1: 1.9 fold reduction, p = 0.01 and adipoR2 2.2 fold
reduction, p= 0.05) (Table 1B).
Cell-type specific downregulation of adiponectin receptors
To identify whether the effects of LPS in vivo reflect a direct effect of LPS treatment on
specific cell types, we examined relevant cell lines, using LPS as a direct stimulus in cell
cultures. We found that adiponectin receptor gene expression differed in adipocytes and
myocytes: in adipocytes, receptor down-regulation was restricted to adipoR2 at higher
doses of LPS (1 and 10 µg/ml) (2.5 fold reduction, p= 0.02 and 3.9 fold reduction, p= 0.01
respectively). This change was observed only in cells treated for 4 h (Fig. 1) while those
treated for 24 h (Fig. 2) exhibited no response.
In myocytes, only a minimal change in receptor gene expression following treatment
with LPS was detectable. There was a small, but statistically significant down-regulation in
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Table 1 Adiponectin receptor gene expression in murine tissue depots. Relative change adiponectin
receptor gene expression in mouse tissue depots 4 h (A) and 24 h (B) after treatment with LPS 25 mg/kg.
Gene expression was determined by real-time PCR. Relative gene expression was calculated using the
2-ddCt method and p < 0.05 was considered significant. The reference group for calculations was the
control group (ip saline injection) and housekeeping gene was β-actin.
4 h AdipoR1 AdipoR2
(A)
2-ddCt p value 2-ddCt p value
Control 1 1
Liver 0.544 0.05 0.371 0.008*
Muscle 0.102* 0.017* 0.162 0.39
EF 0.671 0.48 0.543 0.24
PRF 0.627* 0.0087* 0.231 0.0043*
SCF 0.821 0.81 0.348 0.041*
24 h AdipoR1 AdipoR2
(B)
2-ddCt p value 2-ddCt p value
Control 1 1
Liver 0.614 0.09 0.650 0.148
Muscle 0.509* 0.01* 0.448 0.05*
EF 1.01 0.47 0.852 0.55
PRF 0.801 0.27 0.657 0.198
SCF 0.824 0.47 1.058 0.98
Notes.
* p < 0.05.
SEM, standard error of mean; EF, Epididymal fat; PRF, Peri-renal fat; SCF, Subcutaneous fat.
adipoR1 after treatment with 5 µg/ml LPS for 4 h (p= 0.02) (Fig. 3) and small increases in
adipoR2 after 24 h (p < 0.01) (Fig. 4).
Adiponectin gene expression is downregulated early after LPS
stimulation
Adiponectin receptor down-regulation was accompanied by a dose-dependent reduction
in adiponectin gene expression in 3T3-L1 adipocytes. This downregulation was only
observed 4 h (Fig. 5) after stimulation with LPS, while 24 h after treatment no significant
changes were found (Fig. 6). This is in line with previous reports showing a normalisation
of adiponectin gene expression 24 h after treatment of mice with LPS (Leuwer et al., 2009).
DISCUSSION
LPS induces an acute inflammatory response in most organs, including WAT, liver and
skeletal muscle. These changes extend to several metabolic pathways, including the
adiponectin system. Thus far, the down-regulation of adiponectin and its receptors has
been well described in chronic conditions associated with low-grade inflammation such
as obesity and type II DM (Kadowaki et al., 2006; Kern et al., 2003). Chronic low-grade
inflammation leads to elevated concentrations of pro-inflammatory cytokines such as
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Figure 1 Adiponectin receptor gene expression in 3T3-L1 adipocytes 4 h following LPS challenge. Rel-
ative change adiponectin receptor gene expression in mouse adipocyte cell line (3T3-L1) incubated for
4 h (n = 6 run in duplicate) with varying concentrations of LPS. Gene expression was determined
by real-time PCR. Relative gene expression was calculated using the 2-ddCt method and p < 0.05
was considered significant. Error bars correspond to Standard Error of Mean (∗p < 0.05, ∗∗p < 0.01).
Housekeeping gene was β-actin. (R1, AdipoR1; R2, AdipoR2).
Figure 2 Adiponectin receptor gene expression in 3T3-L1 adipocytes 24 following LPS challenge. Rel-
ative change adiponectin receptor gene expression in mouse adipocyte cell line (3T3-L1) incubated for
24 h (n = 6 run in duplicate) with varying concentrations of LPS. Gene expression was determined
by real-time PCR. Relative gene expression was calculated using the 2-ddCt method and p < 0.05
was considered significant. Error bars correspond to Standard Error of Mean (∗p < 0.05, ∗∗p < 0.01).
Housekeeping gene was β-actin. (R1, AdipoR1; R2, AdipoR2).
TNF-α and Interleukin-6 (IL-6) which may play a role and both mediators suppress
adiponectin production (Fantuzzi, 2008). Our results demonstrate that adiponectin
receptor gene expression is altered in response to LPS challenge. To the best of our
knowledge, change in adiponectin receptor gene expression in response to an acute LPS
challenge has not been investigated before in a mouse model of severe sepsis.
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Figure 3 Adiponectin receptor expression in C2C12 myocytes 4 h following LPS challenge. Relative
change adiponectin receptor gene expression in mouse isolated myocytes (C2C12) incubated for 4 h
(n = 6 run in duplicate) with varying concentrations of LPS. Gene expression was determined by real-
time PCR. Relative gene expression was calculated using the 2-ddCt method and p< 0.05 was considered
significant. Error bars correspond to Standard Error of Mean (∗p< 0.05, ∗∗p< 0.01). Housekeeping gene
was β-actin. (R1, AdipoR1; R2, AdipoR2).
Figure 4 Adiponectin receptor expression in C2C12 myocytes 24 h following LPS challenge. Relative
change adiponectin receptor gene expression in mouse isolated myocytes (C2C12) incubated for 24 h
(n = 6 run in duplicate) with varying concentrations of LPS. Gene expression was determined by real-
time PCR. Relative gene expression was calculated using the 2-ddCt method and p< 0.05 was considered
significant. Error bars correspond to Standard Error of Mean (∗p< 0.05, ∗∗p< 0.01). Housekeeping gene
was β-actin. (R1, AdipoR1; R2, AdipoR2).
In acute inflammatory processes, adipose tissue responds to systemic endotoxaemia in a
similar fashion by producing early rises in inflammatory cytokine expression, in particular
IL-6 and TNF-α. In endotoxaemic mice, these changes have been demonstrated to be
accompanied by reduced adiponectin gene and protein expression in multiple depots of
adipose tissue (Leuwer et al., 2009). We further support these findings by demonstrating
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Figure 5 Adiponectin gene expression in 3T3-L1 adipocytes 4 h following LPS challenge. Relative
change adiponectin receptor gene expression in mouse adipocyte cell line (3T3-L1) incubated for 4 h
(n = 6 run in duplicate) varying concentrations of LPS. Gene expression was determined by real-time
PCR. Relative gene expression was calculated using the 2-ddCt method and p < 0.05 was considered
significant. Error bars correspond to Standard Error of Mean (∗p < 0.05, ∗∗p < 0.01). Housekeeping
gene was β-actin. (R1, AdipoR1; R2, AdipoR2).
Figure 6 Adiponectin gene expression in 3T3-L1 adipocytes 24 h following LPS challenge. Relative
change adiponectin receptor gene expression in mouse adipocyte cell line (3T3-L1) incubated for 24 h
(n = 6 run in duplicate) varying concentrations of LPS. Gene expression was determined by real-time
PCR. Relative gene expression was calculated using the 2-ddCt method and p < 0.05 was considered
significant. Error bars correspond to Standard Error of Mean (∗p < 0.05, ∗∗p < 0.01). Housekeeping
gene was β-actin. (R1, AdipoR1; R2, AdipoR2).
adiponectin gene expressions down-regulation in cultured 3T3-L1 adipocytes. However in
a recent report, the use of lower LPS doses in female rats has produced conflicting results:
concentrations of adiponectin in visceral and subcutaneous WAT remained unchanged
or even increased (Iwasa et al., 2014). Gender differences as well as the use of low LPS
(5 mg/kg compared to 25 mg/kg LPS in our study) may contribute to this discrepancy.
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Similarly, in human volunteers, intravenous administration of low dose endotoxin has
failed to reduce circulating adiponectin despite acute rises in inflammatory cytokines
(Anderson et al., 2007; Keller et al., 2003). Since mild endotoxaemia may neither reflect
severe LPS responses nor human sepsis, appropriately used a high-dose LPS model to
induce a peracute activation of the immune system.
The mouse model used in this study represents severe sepsis and is known to produce
sharp but transient increases in pro-inflammatory cytokines accompanied by severe
reductions in cardiac output and blood pressure (Dyson & Singer, 2009; Remick &
Ward, 2005). Although human sepsis differs from experimental endotoxaemia, a study
investigating the adiponectin system in human sepsis identified significantly lower mean
circulating adiponectin in septic patients, which supports the concept that the adiponectin
system is downregulated in acute infection and inflammation (Venkatesh et al., 2009).
Our animal model demonstrated a significant but depot-dependent down-regulation
of adiponectin receptors in adipose tissue, skeletal muscle and liver. The time points
were chosen to demonstrate early changes and also potential normalisation occurring
at 24 h. The response from adipose tissue varied depending on the depot investigated. In
perirenal (visceral) fat, both adiponectin receptor subtypes were down-regulated, while
in subcutaneous fat only adipoR2 down-regulation was observed. There were no changes
in epididymal fat depots. This may reflect redistribution of tissue perfusion following the
inflammatory insult or could alternatively result from the metabolic differences between
visceral and subcutaneous fat (Bergman et al., 2007; Nannipieri et al., 2007).
Receptor down-regulation in fat depots and adipocyte cell line cultures was transient.
In adipocytes, we demonstrated a rapid onset dose-dependent reduction in adipoR2 gene
expression within 4 h of LPS treatment which was accompanied by reduced adiponectin
mRNA levels. Interestingly, there was no change in adipoR1 expression. This is in
contrast to previous results which demonstrated down-regulation of both receptors by
Staphylococcus Aureus-derived peptidoglycans after only 3 h of treatment in 3T3-L1
adipocytes (Ajuwon, Banz & Winters, 2009), despite staphylococcal proteins being capable
of inducing cytokine release by 3T3-L1 adipocytes (Vu et al., 2013).
In vivo, factors other than LPS contribute to the down-regulation of the adiponectin
system in early acute inflammation. It has previously been demonstrated that insulin
has an inhibitory effect on adipoR1 expression in 3T3-L1 adipocytes (Inukai et al.,
2005). Therefore, high insulin levels associated with endotoxaemia and infection may
have influenced the down-regulation of adipoR1 gene expression observed in our study
(Fasshauer et al., 2002). Adiponectin itself also regulates adiponectin receptor expression
(Mistry et al., 2006) and could have affected expression in our in vivo model. However, the
decrease in adipoR2 gene expression in 3T3-L1 adipocytes precedes changes in adiponectin
gene expression and therefore supports the concept that LPS induces down-regulation
of this receptor subtype by mechanisms independent of adiponectin. The role of other
metabolic changes including insulin resistance, acidosis and hypoxia remain to be
investigated in this context.
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In skeletal muscle, there was a prolonged effect of LPS on adiponectin receptor
expression. This effect again was limited to in-vivo experiments and not seen in the
myocyte cell line (C2C12). It is known that skeletal muscle produces myokines during
exercise and under inflammatory conditions when glycogen stores are low (Pedersen,
2009; Pedersen & Febbraio, 2008). Myokines, including IL-6 and other pro-inflammatory
cytokines, exert paracrine effects locally on the skeletal muscle as well as endocrine effects
when they are released into the systemic circulation (Pedersen, 2009; Pedersen & Febbraio,
2008). The lack of endocrine effects in a cell culture model may account for the discrepancy
between in-vivo and in-vitro models.
Evidence suggests that adiponectin receptors may represent two distinct entities (Bluher
et al., 2006). AdipoR1 deficient mice have been shown to have impaired glucose tolerance,
insulin resistance and increased endogenous production of glucose (Yamauchi et al., 2007),
while adipoR2 knock-out mice are lean, resistant to diet-induced obesity, weight gain
and hepatic steatosis, and display reduced plasma cholesterol and lower fasting insulin.
However, their glucose tolerance is impaired as demonstrated by increased plasma insulin
concentrations (Bjursell et al., 2007; Yamauchi et al., 2007). This indicates that receptor
regulation may be tissue-specific and subtype specific.
While adipoR1 is ubiquitously expressed, including abundant expression in skeletal
muscle, adipoR2 is most abundantly expressed in the liver (Kadowaki et al., 2006).
Regulation of adipoRs in the liver is less well described than in skeletal muscle, but there
is some evidence that PPARα agonists increase adipoR expression (Tsuchida et al., 2005).
Furthermore, incubation of hepatocytes or myocytes with insulin reduces the expression
of adipoR1 and adipoR2 (Tsuchida et al., 2004), indicating that insulin may play a direct
role in adiponectin receptor expression regulation. Thus, insulin resistance associated
with systemic LPS challenge may be involved in the adiponectin receptor down-regulation
observed in the liver extracts in our in vivo model. Two other studies have confirmed the
down-regulation of adipoR2 in the hepatic tissue of mildly endotoxaemic male and female
rats (Iwasa et al., 2014; Sakai et al., 2013) but without change in adipoR1 expression.
Our study is limited in that we did not determine circulating adiponectin, glucose or
insulin levels in the in-vivo model. Hence, further experiments to investigate the relation
between insulin, glucose and triglyceride levels and adiponectin receptor expression
are required. In addition, the translation of changes in gene expression into changes in
protein measurement requires to be elucidated. Although a trend towards normalisation in
adiponectin receptor expression was demonstrated after 24 h, our experiments only pro-
vide results for the early stages of endotoxaemia. Further investigations including longer
term consequences of adiponectin receptor down-regulation in systemic inflammation
are therefore warranted. Our results only allow conclusions for male animals, gender
differences in adiponectin receptor expression have been described in a previous report
(Iwasa et al., 2014). The comparison of LPS doses from animal experiments to cell lines is
difficult as response to external LPS challenge varies between cell lines. Thus, we accept that
there are limitations in comparing the doses of LPS used in both experimental setups.
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CONCLUSIONS
Taken together, the down-regulation of adiponectin receptors in muscle, liver and fat de-
pots in endotoxaemia may contribute to insulin resistance and hyperglycaemia frequently
found in clinical conditions associated with acute inflammation. The trend towards
normalisation of adiponectin receptor expression after 24 h in vivo may reflect activation
of counter-regulatory mechanisms within the body to limit the pro-inflammatory response
and the metabolic derangements. This counterrregulation is unlikely to represent clinical
improvement as all the mice continued to display overwhelming symptoms of acute
inflammation. Cell culture systems may lack the capacity for effective control of LPS
effects, which could explain the longer duration of adiponectin receptor down-regulation
under in vitro conditions.
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